$ATYR News

aTyr Pharma Announces Research Collaboration with Montefiore Einstein

aTyr Pharma Enters Research Collaboration With Albert Einstein College Of Medicine To Develop And Test ATYR2810, Its Monoclonal Antibody That Targets The Neuropilin-2 Receptor

aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry

aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects Of ATYR0101 In Journal Of Biological Chemistry

Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease

aTyr Pharma FDA Alignment Sets Protocol for Phase 3 Efzofitimod Study in Pulmonary Sarcoidosis

aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

aTyr Pharma Reaches FDA Alignment On Protocol For A Phase 3 Study Of Its Lead Therapeutic Candidate Efzofitimod In Patients With Chronic, Symptomatic Pulmonary Sarcoidosis With Restrictive Lung Disease; Expects To Initiate Study-Related Activities In Q4 2026

aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

aTyr Pharma Announces It Expects FDA Response Regarding Its Submitted Protocol For Phase 3 Trial Of Efzofitimod To Treat Pulmonary Sarcoidosis With Restrictive Lung Disease In Mid-September

Update: ATyr Pharma Fiscal Q2 Loss Narrows; Announces Restructuring Plans

aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD

aTyr Pharma CFO Jill Broadfoot To Step Down As Of September 30; To Be Succeeded By Brandon Yaras As Of October 1

aTyr Pharma Q2 EPS $(0.11) Beats $(0.12) Estimate

aTyr Pharma And Kyorin Terminate Collaboration Agreement Effective July 30, 2026; Regains Exclusive Global Rights To Efzofitimod

aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026

aTyr Pharma To Present Subgroup Analysis Of Phase 3 EFZO-FIT Study Of Efzofitimod In Pulmonary Sarcoidosis At WASOG 2026 Congress; Submits Phase 3 Protocol To FDA For Efzofitimod In June

aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

aTyr Pharma Q1 EPS $(0.11) Beats $(0.14) Estimate

aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III Results - Slideshow